The Center for Biosimilars® recaps the top news for the week of May 6, 2019.
Transcript:
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 6.
Number 5: Last week, Coherus BioSciences announced that it has reached a settlement with Amgen over a trade secret case. Separately, Amgen filed a new complaint against Samsung Bioepis.
Number 4: The pan-Canadian Pharmaceutical Alliance and Cancer Care Ontario have partnered to create a new biosimilars initiative.
Number 3: Now that its comment period has closed, the FDA has heard from a variety of stakeholders who asked the agency to reconsider its guidance on biosimilar naming.
Number 2: A new review of the available literature on switching sought to address provider concerns about biosimilars.
Number 1: The idea of giving the Federal Trade Commission more authority to cut through patent thickets blocking biosimilar competition was raised during a hearing of the Senate Judiciary Committee.
Finally, last week, our e-newsletter asked whether you agree with a recent proposal that suggests regulating biologics’ prices rather than continuing to develop the US biosimilars market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.